We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
+0.07%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
+$123M
Cap. Flow
+$41.3M
Cap. Flow %
14.72%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$46.8M
2
RVLP
RVL Pharmaceuticals plc Ordinary Shares
RVLP
+$13.2M

Top Sells

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 73.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$95.7M 34.1%
8,857,268
+4,337,268
+96% +$46.8M
BIOR
2
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$62.4M 22.25%
119,423
-26,165
-18% -$18.8M
CMAX
3
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$34.5M 12.29%
149,574
– –
RVLP
4
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$8.8M 3.14%
+8,148,832
New +$13.2M
SCTL
5
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$3.77M 1.34%
2,202,420
– –

Similar funds

BGC
Birch Grove Capital New York $9.51M AUM 0.22% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
JDR
Jay D. Rosenbaum $6.69M AUM 4.68% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
KIM
Kaizen Investment Management Singapore $6.23M AUM
RJTCONH
Raymond James Trust Company of New Hampshire Portsmouth, New Hampshire $12.1M AUM 28.84% 1-Year Est. Return
HSC
Harbor Spring Capital New York $12.3M AUM
HVM
Harvest Volatility Management Norwalk, Connecticut $4.39M AUM 13.08% 1-Year Est. Return

Athyrium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Athyrium Capital Management held 6 positions worth $280M, up 78% from $158M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Athyrium Capital Management deployed $41.3M of net new capital in Q4 2021, opening 1 new position and adding to 1 existing holding. Its largest new stake was RVL Pharmaceuticals plc Ordinary Shares: 8,148,832 shares worth $8.8M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Biora Therapeutics, Inc. Common Stock, an estimated $18.8M trimmed.

  • Athyrium Capital Management's largest Q4 2021 buy was RVL Pharmaceuticals plc Ordinary Shares: 8,148,832 shares worth $8.8M.
  • Athyrium Capital Management added most to Amryt Pharma plc American Depositary Shares in Q4 2021, an estimated $46.8M increase.
  • Athyrium Capital Management's biggest Q4 2021 reduction was Biora Therapeutics, Inc. Common Stock, cutting an estimated $18.8M.
  • Athyrium Capital Management's ten largest holdings make up 100% of its $280M portfolio in Q4 2021.
  • Athyrium Capital Management opened 1 new position and closed 0 in Q4 2021.
  • Athyrium Capital Management's portfolio value rose 78% quarter-over-quarter to $280M.

Based on Athyrium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.